Don't know.
From what's been said publicly they would prefer to sell products into the non-hospital, clinical podiatry space using an established sales force rather than developing their own.
They must think that realistic opportunities might become available -- it's not pie-in-the-sky, wishful thinking. It strikes me that DW is not a fantasist and is comfortable with thinking along such lines as he has deep M&A experience.
PNV - Banter and General Comments, page-11310
-
- There are more pages in this discussion • 1,722 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.02 |
Change
-0.040(1.94%) |
Mkt cap ! $1.395B | |||
| Open | High | Low | Value | Volume |
| $2.01 | $2.04 | $2.00 | $1.537M | 762.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 41008 | $2.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.03 | 5942 | 2 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |